IL6 and arthritic joint disease: Miriam Granado et al. demonstrated that the activation agent GHRP-2 significantly reduces IL-6 levels released by macrophages induced by LPS and inhibits inflammatory responses in rats with arthritis, suggesting that GHRP-2 may be a promising therapeutic candidate for targeting the GHS-R1a receptor for arthritis treatment [80].